{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=12&q=hormone-sensitive", "query": { "q": "hormone-sensitive", "condition": "Prostate Cancer", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 158, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=13&q=hormone-sensitive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=11&q=hormone-sensitive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T21:31:25.364Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06734130", "title": "Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Sensitive Prostate Cancer" ], "interventions": [ { "name": "Luteinizing Hormone-Releasing Hormone (LHRH) analog", "type": "DRUG" }, { "name": "Androgen Receptor Signal Inhibitor (ARSI)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2025-01-10", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06734130" }, { "nct_id": "NCT06991556", "title": "An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer" ], "interventions": [ { "name": "JSB462", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 168, "start_date": "2025-07-07", "completion_date": "2035-10-04", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 21, "location_summary": "La Jolla, California • Santa Monica, California • Denver, Colorado + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06991556" }, { "nct_id": "NCT07028853", "title": "This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration Sensitive Prostate Cancer (mCSPC)", "Hormone Sensitive Prostate Cancer", "Prostate Cancer", "Cancer of the Prostate" ], "interventions": [ { "name": "Mevrometostat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1000, "start_date": "2025-09-28", "completion_date": "2034-12-08", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 127, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 89 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07028853" }, { "nct_id": "NCT04477512", "title": "Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone Refractory Prostate Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Peripheral blood collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2021-02-19", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477512" }, { "nct_id": "NCT03827473", "title": "Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Sensitive Prostate Carcinoma", "Metastatic Prostatic Adenocarcinoma", "Stage IV Prostate Cancer", "Stage IVA Prostate Cancer", "Stage IVB Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1, "start_date": "2019-02-08", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2020-06-25", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03827473" }, { "nct_id": "NCT03298087", "title": "Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Newly Diagnosed Oligometastatic Prostate Cancer" ], "interventions": [ { "name": "radical prostatectomy", "type": "PROCEDURE" }, { "name": "stereotactic body radiotherapy", "type": "RADIATION" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "apalutamide", "type": "DRUG" }, { "name": "abiraterone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 28, "start_date": "2018-07-01", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2025-08-01", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 3, "location_summary": "Long Beach, California • West Los Angeles, California • Richmond, Virginia", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "West Los Angeles", "state": "California" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298087" }, { "nct_id": "NCT06957691", "title": "Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Cancer (Adenocarcinoma)", "Prostate Cancer Metastatic Disease", "Prostate Cancer Recurrent", "Prostate Carcinoma", "Prostate Neoplasm", "Prostate Adenocarcinoma", "Prostate Cancer With Bone Metastasis", "Vasomotor Disturbance", "Vasomotor Symptoms", "Vasomotor Symptoms (VMS)", "Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men", "Vasomotor Symptoms; Hot Flashes", "Androgen Deprivation Therapy", "Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma", "Androgen-deprivation Therapy", "Hot Flashes", "Hot Flushes", "Hot Flushes and/or Sweats" ], "interventions": [ { "name": "fezolinetant - reference formulation", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shehzad Basaria, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "MALE", "summary": "40 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2026-01-14", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06957691" }, { "nct_id": "NCT07674771", "title": "Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Prostate Cancer", "Castration Sensitive Prostate Cancer", "Metastatic Prostate Cancer", "Adaptive Radiotherapy" ], "interventions": [ { "name": "Drug: 68-Ga PSMA11", "type": "DRUG" }, { "name": "Adaptive stereotactic ablative radiotherapy (SABR)", "type": "RADIATION" }, { "name": "68Ga-PSMA-11", "type": "DRUG" }, { "name": "Adaptive stereotactive ablative radiotherapy (SABR)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2026-10", "completion_date": "2029-06-15", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07674771" }, { "nct_id": "NCT03246347", "title": "A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "ADT+Docetaxel+Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2017-08-23", "completion_date": "2028-03", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03246347" }, { "nct_id": "NCT02491411", "title": "Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 5, "start_date": "2015-09", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2018-07-12", "last_synced_at": "2026-10-14T21:31:25.364Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02491411" } ] }